GHRS Stock Price, Analysis & Fundamentals

Analysis

GH Research PLC is a biotechnology company operating in the healthcare sector. With a market capitalization of $958.97M and approximately 50 employees, it represents a relatively small player within its industry. The company's financial health appears to be strained, with marginal profitability metrics: Gross Margin stands at 0.0%, Operating Margin is also 0.0%, and Profit Margin is 0.0%. Additionally, the net income (TTM) is -$42,923,000, while EBITDA is -$56,822,000 and Free Cash Flow is -$29,893,500. The company's cash position is $288.51M, but it also has a significant debt of $582,000. Valuation metrics paint an uncertain picture: the P/E Ratio (TTM) is N/A, while the Forward P/E is -9.85 and EV/EBITDA is -9.39. The Price to Book ratio stands at 3.29.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About GH Research PLC

GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Visit website →

GHRS

Price History (1Y)

Analysis

About GH Research PLC

Key Statistics

Company Info